• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Cosmos Health Inc.

    6/5/26 4:55:48 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care
    Get the next $COSM alert in real time by email
    DEFA14A 1 cosm_defa14a.htm DEFA14A cosm_defa14a.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    AMENDMENT NO. 1

    TO

    SCHEDULE 14A

    (RULE 14a-101)

     

    INFORMATION REQUIRED IN

    PROXY STATEMENT

     

    SCHEDULE 14A INFORMATION

     

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934 (Amendment No. 1)

     

    Filed by the Registrant ☒ 

    Filed by a Party other than the Registrant ☐

     

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

    Definitive Proxy Statement

    ☒

    Definitive Additional Materials

    ☐

    Soliciting Material under §240.14a-12

     

    Cosmos Health Inc.

    (Name of Registrant as Specified In Its Charter)

     

    ____________________________________________________

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    ☒

    No fee required.

    ☐

    Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

    (1)

    Title of each class of securities to which transaction applies:

     

     

     

    (2)

    Aggregate number of securities to which transaction applies:

     

     

    (3)

    Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

     

     

    (4)

    Proposed maximum aggregate value of transaction:

     

     

    (5)

    Total fee paid:

     

     

    ☐

    Fee paid previously with preliminary materials.

     

     

    ☐

    Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11 (a)(2) and identity the filing for which the offsetting fee was paid previously. Identity the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

     

     

     

     

    (1)

    Amount Previously Paid:

     

     

     

     

    (2)

    Form, Schedule or Registration Statement No.:

     

     

     

     

    (3)

    Filing Party:

     

     

     

     

    (4)

    Date Filed:

     

     

     

      

    Explanatory Note

     

    This Amendment No. 1 to Schedule 14A (this “Amendment”) is being filed solely to amend and replace the sample proxy card included in the Definitive Proxy Statement filed by Cosmos Health Inc. (the “Company”) with the Securities and Exchange Commission on June 2, 2026 (the “Proxy Statement”). After filing the Proxy Statement, the Company discovered that, due to a clerical error, an incorrect version of the sample proxy card was inadvertently filed with the Proxy Statement.

     

    Please note that no changes have been made to the body of the Proxy Statement and that a correct version of the proxy card has been included in the Proxy Statement being mailed to the Company’s stockholders. This Amendment applies only to the version of the sample proxy card originally filed with the Proxy Statement.

     

     
    2

     

     

    COSMOS HEALTH INC.

     

    THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS

     

    ANNUAL MEETING OF STOCKHOLDERS –  JULY 15, 2026 AT 9:00 AM LOCAL TIME

     

     

     

    The undersigned hereby appoints Grigorios Siokas and Georgios Terzis, and each of them, with full power of substitution and power to act alone, as proxies to vote all the shares of Common Stock which the undersigned would be entitled to vote if personally present and acting at the Annual Meeting of Shareholders of Cosmos Health Inc., to be held on  July 15, 2026 at 9:00 a.m., at the Company’s U.S. offices at 141 West Jackson Boulevard, Suite 4236, Chicago, Illinois 60604, and at any adjournments or postponements thereof, as follows:

     

    (CONTINUED AND TO BE SIGNED ON REVERSE SIDE.)

     

     

    VOTING INSTRUCTIONS

     

    Please mark, sign, date, and return this Proxy Card promptly using the enclosed envelope.

     

     

    If you vote by phone, fax or internet, please DO NOT mail your proxy card.

     

    Vote by fax

     

    Complete the reverse portion of this Proxy Card and Fax to 202-521-3464

     

    Vote by telephone

     

     

     

    ·

    Call toll-free designated number 1-866-752-VOTE(8683). There is NO CHARGE for this call.

     

     

    ·

    Follow the instructions provided by the recorded message.

     

     

     

     

     

    Electronic Voting Instructions

     

     

     

     

     

     

    ·

    Log on to the Internet and go to

     

     

     

    https://www.iproxydirect.com/COSM

     

     

    ·

    Follow the steps outlined on this secured Web site.

     

     

     
    3

     

     

    ANNUAL MEETING OF THE STOCKHOLDERS OF

    COSMOS HEALTH INC.

    PLEASE COMPLETE, DATE, SIGN AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE.

    PLEASE MARK YOUR VOTE IN BLUE OR BLACK INK AS SHOWN HERE: ☐ 

     

     

    PROXY SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS

     

     

     

     

     

    Proposal 1

     

    →

    FOR

    ALL

     

    WITHHOLD

    ALL

     

    FOR ALL

    EXCEPT

     

     

     

     

    Election of Directors:

     

    ☐

     

    ☐

     

    ☐

     

     

     

     

    Grigorios Siokas

     

    ☐

     

    ☐

     

    ☐

     

     

     

     

    Demetrios G. Demetriades

     

    ☐

     

    ☐

     

    ☐

     

    Control ID:

     

     

    John J. Hoidas

     

    ☐

     

    ☐

     

    ☐

     

    REQUEST ID:

     

     

    Dr. Anastasios Aslidis

     

    ☐

     

    ☐

     

    ☐

     

     

     

     

    Theodoros C. Karkantzos

     

    ☐

     

    ☐

     

    ☐

     

     

     

     

     

    Suhel Bhutawala

     

    ☐

     

    ☐

     

    ☐

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Proposal 2

     

    →

    FOR

     

    AGAINST

     

    ABSTAIN

     

     

     

     

    Ratification of the appointment of the Company’s independent registered public accounting

     

    ☐

     

    ☐

     

    ☐

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Proposal 3

     

    →

    FOR

     

    AGAINST

     

    ABSTAIN

     

     

     

     

    Approval of the 2026 Omnibus Equity Incentive Plan

     

    ☐

     

    ☐

     

    ☐

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Proposal 4

     

    →

    FOR

     

    AGAINST

     

    ABSTAIN

     

     

     

     

    Approval of designation and issuance of Series B Preferred Stock

     

    ☐

     

    ☐

     

    ☐

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    MARK “X” HERE IF YOU PLAN TO ATTEND THE MEETING: ☐

    The undersigned acknowledges receipt from the Company before the execution of this proxy of the Notice of Annual Meeting of Shareholders, a Proxy Statement for the Annual Meeting of Shareholders and the 2025 Annual Report on Form 10-K the proxy will be voted (1) “for” the election of each of the nominees for director; (2) ““for” the ratification of the appointment of the Company’s independent registered public accounting (3) “for” the approval of the 2026 Omnibus Equity Incentive Plan and (4) for the approval of designation and issuance of Series B Preferred Stock.

     

     

     

     

    MARK HERE FOR ADDRESS CHANGE   ☐  New Address (if applicable):

    ____________________________

    ____________________________

    ____________________________

     

    IMPORTANT: Please sign exactly as your name or names appear on this Proxy. When shares are held jointly, each holder should sign. When signing as executor, administrator, attorney, trustee or guardian, please give full title as such. If the signer is a corporation, please sign full corporate name by duly authorized officer, giving full title as such. If signer is a partnership, please sign in partnership name by authorized person.

     

    Dated: ________________________, 2026

     

     

     

    (Print Name of Stockholder and/or Joint Tenant)

     

     

    (Signature of Stockholder)

     

     

    (Second Signature if held jointly)

     

     
    4

     

    Get the next $COSM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COSM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $COSM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Siokas Grigorios bought $145,000 worth of shares (388,532 units at $0.37), increasing direct ownership by 5% to 8,861,914 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    2/13/26 10:05:37 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $120,000 worth of shares (291,262 units at $0.41), increasing direct ownership by 4% to 8,473,382 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    2/12/26 2:20:08 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $45,000 worth of shares (90,325 units at $0.50), increasing direct ownership by 1% to 8,182,120 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    1/26/26 11:48:12 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $COSM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cosmos Health Achieves Pan-European Distribution for Sky Premium Life Across All 27 EU Member States Through Leading E-Commerce Platform Skroutz

    CHICAGO, June 04, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its proprietary brand, Sky Premium Life, is now available for shipment across all 27 European Union Member States through Skroutz, significantly expanding the brand's international reach. A total of 96 Sky Premium Life products are now accessible to consumers across all 27 European Union Member States through Skroutz, with shipments reaching key markets across Western Europe, Northern Europe, and Central and Eastern Europe. The countries covered include Austria, Belgium, Bulgaria, Croatia, Cyprus,

    6/4/26 3:57:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health Identifies Approximately $20 Million in Non-Core Assets Available for Monetization to Accelerate Growth and Unlock Shareholder Value

    Company identifies real estate, digital assets, and marketable securities, among others, as potential sources of liquidity — with a combined value of approximately $20 millionProceeds could fund a meaningful acquisition or eliminate debt entirelyCompany remains fully committed to its core healthcare operations CHICAGO, June 04, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced it is exploring the monetization of non-core assets, having identified approximately $20 million in assets that can be converted to liquidity without impacting the Company's operational capabili

    6/4/26 9:25:00 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health Provides Balance Sheet Update: Highlights European Investment Bank Financing Discussions for up to €25M, Eliminates 38% of Warrant Overhang with No Dilution; Reaffirms Growth Trajectory; Notes No Known Business Reason for Recent Share Price Decline

    Significant Deleveraging: Total liabilities decreased by $4.5 million, or 9.6%, quarter-over-quarter, while stockholders' equity increased 7.6%Landmark Financing: R&D division in discussions with the European Investment Bank for financing of up to €25 millionCapital Structure Simplification: 4,874,126 Series B Warrants expired unexercised, eliminating ~38% of total warrant overhang with zero shareholder dilutionReal Estate Value: Wholly-owned facilities independently valued at approximately $15 million — exceeding current market capitalization  Balance Sheet Transformation: Guidance projects stockholders' equity of $92.3 million by 2029, driven by a growing cash position of $62.9 million fro

    6/2/26 8:00:00 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $COSM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Siokas Grigorios bought $145,000 worth of shares (388,532 units at $0.37), increasing direct ownership by 5% to 8,861,914 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    2/13/26 10:05:37 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $120,000 worth of shares (291,262 units at $0.41), increasing direct ownership by 4% to 8,473,382 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    2/12/26 2:20:08 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $45,000 worth of shares (90,325 units at $0.50), increasing direct ownership by 1% to 8,182,120 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    1/26/26 11:48:12 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $COSM
    SEC Filings

    View All

    SEC Form DEFA14A filed by Cosmos Health Inc.

    DEFA14A - Cosmos Health Inc. (0001474167) (Filer)

    6/5/26 4:55:48 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    SEC Form DEF 14A filed by Cosmos Health Inc.

    DEF 14A - Cosmos Health Inc. (0001474167) (Filer)

    6/2/26 4:30:20 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    SEC Form PRE 14A filed by Cosmos Health Inc.

    PRE 14A - Cosmos Health Inc. (0001474167) (Filer)

    5/22/26 4:30:14 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $COSM
    Leadership Updates

    Live Leadership Updates

    View All

    Cosmos Health Provides Update; Evaluates Options to Address Valuation Disconnect; Will Issue Updated Guidance Following FY 2025 Results; Record Growth Continues as Significant U.S. Expansion Underway, with Additional $12M+ in High-Margin Revenue Projected; Important R&D Updates Expected Following Finalization of Certain Anticipated Transactions

    Continues to deliver record revenue and improving operating metricsSignificant expansion in the United States underway, with NOOR and other Sky Premium Life products expected to drive strong profitability supported by gross margins of approximately 75%NOOR Collagen alone is projected to generate more than $12 million in annualized revenue Strong growth expected ahead, driven by organic progress and M&A pipeline including a recent LOI to acquire an $11.5 million pharmacy distribution network Holds valuable non-core strategic real estate and digital assets with an estimated fair market value exceeding $18 million, providing meaningful balance sheet flexibilityEvaluating potential monetization

    3/19/26 12:45:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board

    CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the appointment of Dr. Dimitrios Iliopoulos to its Advisory Board, where he will support the Company's biotechnology initiatives, with a focus on AI-driven drug discovery and clinical-stage therapeutic development. Dr. Iliopoulos is a world-renowned expert in artificial intelligence, drug discovery, and drug development. He currently serves as Co-Founder and CEO of Athos Therapeutics Inc., an AI software and clinical-stage biotechnology company focused on developing precision therapeutics for autoimmun

    2/24/26 12:30:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million

    CHICAGO, April 16, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today reported financial results for the full year ended December 31, 2024. Full Year 2024 Financial Highlights Income Statement: FY 2024 performance was marked by revenue growth, an increase in R&D investments, and a substantial reduction in operating expenses, while bottom-line results were impacted by the absence of non-recurring gain

    4/16/25 12:45:15 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $COSM
    Financials

    Live finance-specific insights

    View All

    Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000

    CHICAGO, April 30, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 1,466,764 common shares, valued at $526,000, across five transactions between April 21, 2025, and April 24, 2025. As a result of these transactions, Mr. Siokas now beneficially owns 5,582,066 common shares in Cosmos Health. Greg S

    4/30/25 12:50:09 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days

    CHICAGO, IL / ACCESS Newswire / January 21, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 647,809 common shares, valued at $425,000, across six transactions between December 20, 2024, and January 17, 2025.As a result of these transactions, Mr. Siokas now beneficially owns 4,164,789 common shares in Cosmos Health.Greg Si

    1/21/25 3:00:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health Issues Letter to Shareholders

    CHICAGO, IL / ACCESSWIRE / November 12, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its Chief Executive Officer, Greg Siokas, has issued the following letter to the Company's shareholders.Dear Cosmos Health Shareholders,It has been just over a year since my previous shareholder letter, and I would like to express my sincere gratitude for your continued support. We have achieved many positive milestone

    11/12/24 12:01:41 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $COSM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cosmos Health Inc.

    SC 13G/A - Cosmos Health Inc. (0001474167) (Subject)

    11/14/24 4:50:24 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G filed by Cosmos Health Inc.

    SC 13G - Cosmos Health Inc. (0001474167) (Subject)

    2/14/24 3:33:29 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13D/A filed by Cosmos Health Inc. (Amendment)

    SC 13D/A - Cosmos Health Inc. (0001474167) (Subject)

    7/25/23 4:06:11 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care